Details for Patent: 10,689,377

✉ Email this page to a colleague

Patent 10,689,377 protects KRAZATI and is included in one NDA.

This patent has forty patent family members in thirty-one countries.

Patent landscape, scope, and claims:

Title:	KRas G12C inhibitors
Abstract:	The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
Inventor(s):	Blake James F., Burgess Laurence E., Chicarelli Mark Joseph, Christensen James Gail, Cook Adam, Fell Jay Bradford, Fischer John P., Marx Matthew Arnold, Mejia Macedonio J., Savechenkov Pavel, Vigers Guy P. A., Smith Christopher Ronald, Rodriguez Martha E.
Assignee:
Application Number:	US16191190
Patent Claim Types: see list of patent claims
More… ↓ ⤷ Subscribe

These patents are from the daily update and have not yet been integrated into the regular database

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Bristol	KRAZATI	adagrasib	TABLET	216340	Dec 12, 2022	RX	Yes	10,689,377	Y	Y		⤷ Subscribe	U-3490	TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY
Bristol	KRAZATI	adagrasib	TABLET	216340	Dec 12, 2022	RX	Yes	10,689,377	Y	Y		⤷ Subscribe	U-3953	TREATMENT, IN COMBINATION WITH CETUXIMAB, OF ADULT PATIENTS WITH KRAS G12C-MUTED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER, PER FDA APPROVED TEST, WHERE PRIOR TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Type	>RLD	>Patent No.	>Product	>Substance	>Delist Req.	>Patent Expiration	>Usecode	>Patented / Exclusive Use

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol	KRAZATI	adagrasib	TABLET;ORAL	216340-001	Dec 12, 2022		RX	Yes	Yes	10,689,377	⤷ Subscribe	Y	Y		TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY	⤷ Subscribe
Bristol	KRAZATI	adagrasib	TABLET;ORAL	216340-001	Dec 12, 2022		RX	Yes	Yes	10,689,377	⤷ Subscribe	Y	Y		TREATMENT, IN COMBINATION WITH CETUXIMAB, OF ADULT PATIENTS WITH KRAS G12C-MUTED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER, PER FDA APPROVED TEST, WHERE PRIOR TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3710439	⤷ Subscribe	301279	Netherlands	⤷ Subscribe
European Patent Office	3710439	⤷ Subscribe	CA 2024 00024	Denmark	⤷ Subscribe
European Patent Office	3710439	⤷ Subscribe	PA2024517	Lithuania	⤷ Subscribe
European Patent Office	3710439	⤷ Subscribe	LUC00350	Luxembourg	⤷ Subscribe
European Patent Office	3710439	⤷ Subscribe	2024C/525	Belgium	⤷ Subscribe
European Patent Office	3710439	⤷ Subscribe	122024000035	Germany	⤷ Subscribe
European Patent Office	3710439	⤷ Subscribe	CR 2024 00024	Denmark	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration